Predictmedix Announces Form 20-F Registration Statement has Cleared SEC Comments

Rhea-AI Summary

Predictmedix Inc. (CSE:PMED)(OTCQB:PMEDF) has successfully cleared SEC comments on its Form 20-F registration statement, submitted on June 17, 2021. This registration allows Predictmedix to list equity securities on a U.S. national stock exchange, thus enhancing its reporting and transparency. It is now required to file regular reports with the SEC, providing investors with insights into its business strategies, risk factors, and financial performance. The company aims for further capital market activities to generate long-term value for its shareholders.

Positive

• Cleared SEC comments on Form 20-F, allowing future equity listings in the U.S.
• Enhanced transparency with regular SEC reporting requirements.
• Opportunity to attract U.S. investors and potentially uplist to a national exchange.

Negative

• None.

TORONTO, ON / ACCESSWIRE / October 14, 2021 / Predictmedix Inc. (CSE:PMED)(OTCQB:PMEDF) ("Predictmedix" or the "Company"), an emerging provider of rapid health screening solutions powered by a proprietary artificial intelligence (AI), today announced that its Form 20-F registration statement, voluntary filed with the United States Securities and Exchange Commission (the "SEC") on June 17, 2021, has cleared all comments from the SEC.

Registration as a reporting company with the SEC is a prerequisite for listing equity securities on a national stock exchange in the United States. As a result of its registration, Predictmedix is subject to the reporting requirements of the United States Securities Exchange Act of 1934, as amended. The Company will file annual, quarterly and periodic reports and other such other information as is required with the SEC. The Form 20-F filing provides investors with detailed information about Predictmedix's operations, including an overview of the business strategies, risk factors and financial statements.

"We are pleased to have executed upon this exciting capital markets milestone, better positioning us to share our story with U.S. investors and for an uplist to a national exchange in the United States," said Rahul Kushwah, Chief Operating Officer of Predictmedix. "Any interested investors can download our form 20-F from the SEC website at www.sec.gov. We look forward to continued capital markets execution in the months ahead as we strive to create sustainable, long-term value for our shareholders."

About Predictmedix Inc.

Predictmedix (CSE:PMED)(OTCQB:PMEDF) is an emerging provider of rapid health screening and remote patient care solutions globally. The Company's Safe Entry Stations - powered by a proprietary artificial intelligence (AI) - use multispectral cameras to analyze physiological data patterns and predict a variety of health issues. The Company's current product is able to screen for infectious diseases such as COVID-19, while its technology under development will screen for impairment by drugs or alcohol, or various mental illnesses. Predictmedix's proprietary remote patient care platform under development will empower medical professionals with a suite of AI-powered tools to improve patient health outcomes. To learn more, please visit our website at www.Predictmedix.com or follow us on Twitter, Instagram or LinkedIn.

Investor Relations Contact
Lucas A. Zimmerman
MZ Group - MZ North America
949-259-4987
PMEDF@mzgroup.us
www.mzgroup.us

Caution Regarding Forward-Looking Information:

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the company, including risks related to COVID-19; risks related to the Company's shares, including price volatility due to events that may or may not be within such party's control; reliance on management; and the emergency of additional competitors in the industry.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law.

Disclaimer: "The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time."

SOURCE: Predictmedix

View source version on accesswire.com:
https://www.accesswire.com/668201/Predictmedix-Announces-Form-20-F-Registration-Statement-has-Cleared-SEC-Comments

FAQ

What does the Form 20-F clearance mean for Predictmedix (PMEDF)?

The Form 20-F clearance allows Predictmedix to list its equity securities on a U.S. national stock exchange, enhancing its market presence.

When was Predictmedix's Form 20-F submitted to the SEC?

Predictmedix submitted its Form 20-F to the SEC on June 17, 2021.

What are the reporting requirements for Predictmedix after the SEC clearance?

Post-clearance, Predictmedix must file annual, quarterly, and periodic reports with the SEC, ensuring transparency for investors.

What opportunities does the SEC registration provide to Predictmedix (PMEDF)?

The SEC registration provides Predictmedix the chance to attract U.S. investors and potentially uplist to a national exchange.